REGENXBIO Inc. (RGNX)

REGENXBIO is a clinical-stage gene therapy company whose bull thesis rests on its proprietary NAV AAV vector platform and a pipeline led by RGX-314 (wet AMD and diabetic retinopathy), which addresses multi-billion-dollar chronic disease markets with potentially one-time treatments. The 92.8% YoY revenue decline reflects the absence of a prior collaboration payment and is not indicative of core business deterioration, while a near-unanimous analyst buy consensus (10 of 11 analysts) and a mean price target implying ~57% upside reflect strong pipeline optionality. The key risk is clinical and regulatory execution — any pipeline setback in ongoing RGX-314 trials could materially reprice the stock given the current loss-making position.

• RGX-314 Phase 2/3 ALTITUDE trial readout for diabetic retinopathy — upcoming data could serve as a major de-risking event and potential catalyst for a partnership or NDA filing.
• Potential licensing or collaboration deal leveraging the NAV AAV technology platform, which could provide near-term non-dilutive capital and validate platform value.
• RGX-314 subretinal wet AMD Phase 3 ATMOSPHERE trial progression — continued enrollment milestones or interim data updates expected in the near term could re-rate the stock.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →